Barclays PLC Raises Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Barclays PLC grew its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 25.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 243,316 shares of the biopharmaceutical company’s stock after acquiring an additional 49,443 shares during the quarter. Barclays PLC’s holdings in Lexicon Pharmaceuticals were worth $180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $33,000. Renaissance Technologies LLC purchased a new position in Lexicon Pharmaceuticals during the 4th quarter worth $38,000. Arizona State Retirement System increased its stake in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 16,136 shares during the period. Teacher Retirement System of Texas increased its stake in Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 24,615 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at about $66,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Trading Down 6.5%

Shares of Lexicon Pharmaceuticals stock opened at $0.63 on Wednesday. The firm has a market cap of $227.74 million, a price-to-earnings ratio of -0.84 and a beta of 1.07. Lexicon Pharmaceuticals, Inc. has a 52-week low of $0.28 and a 52-week high of $2.45. The company’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $0.74. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.26 million. As a group, equities research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on LXRX shares. Leerink Partners reissued a “market perform” rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Piper Sandler decreased their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. StockNews.com started coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They set a “sell” rating for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.67.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.